Literature DB >> 22709743

Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects.

Christine E Garnett1, Hao Zhu, Marek Malik, Anthony A Fossa, Joanne Zhang, Fabio Badilini, Jianguo Li, Börje Darpö, Philip Sager, Ignacio Rodriguez.   

Abstract

This White Paper, written collaboratively by members of the Cardiac Safety Research Consortium from academia, industry, and regulatory agencies, discusses different methods to characterize the QT effects for drugs that have a substantial direct or indirect effect on heart rate. Descriptions and applications are provided for individualized QT-R-R correction, Holter bin, dynamic QT beat-to-beat, pharmacokinetic-pharmacodynamic modeling, and QT assessment at constant heart rate. Most of these techniques are optimally performed using continuous electrocardiogram data obtained in clinical studies designed to characterize a drug's effect on the QT interval. An important study design element is the collection of drug-free data over a range of heart rates seen on treatment. The range of heart rates is increased at baseline by using ambulatory electrocardiogram recordings in addition to those collected under semisupine, resting conditions. Discussions in this study summarize areas of emerging consensus and other areas in which consensus remains elusive and provide suggestions for additional research to further increase our knowledge and understanding of this topic.
Copyright © 2012 Mosby, Inc. All rights reserved.

Mesh:

Year:  2012        PMID: 22709743     DOI: 10.1016/j.ahj.2012.02.023

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  49 in total

1.  Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.

Authors:  Jennifer E Hibma; Hagop M Kantarjian; Daniel J DeAngelo; Joseph P Boni
Journal:  Br J Clin Pharmacol       Date:  2019-01-21       Impact factor: 4.335

2.  Correcting QT for Heart Rate When Both are Affected by a Drug.

Authors:  Georg Ferber
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

Review 3.  Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

Review 4.  Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

5.  Baseline correction in parallel thorough QT studies.

Authors:  Joanne Zhang; Qianyu Dang; Marek Malik
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

Review 6.  Scientific white paper on concentration-QTc modeling.

Authors:  Christine Garnett; Peter L Bonate; Qianyu Dang; Georg Ferber; Dalong Huang; Jiang Liu; Devan Mehrotra; Steve Riley; Philip Sager; Christoffer Tornoe; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-05       Impact factor: 2.745

7.  A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.

Authors:  S Y A Cheung; J Parkinson; U Wählby-Hamrén; C D Dota; Å M Kragh; L Bergenholm; T Vik; T Collins; C Arfvidsson; C E Pollard; H K Tomkinson; B Hamrén
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-05-07       Impact factor: 2.745

Review 8.  Beat-to-beat ECG restitution: A review and proposal for a new biomarker to assess cardiac stress and ventricular tachyarrhythmia vulnerability.

Authors:  Anthony A Fossa
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05-12       Impact factor: 1.468

9.  Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study.

Authors:  Sylvain Goutelle; Elodie Sidolle; Michel Ducher; Jacques Caron; Quadiri Timour; Patrice Nony; Aurore Gouraud
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

Review 10.  The role of concentration-effect relationships in the assessment of QTc interval prolongation.

Authors:  Nicholas P France; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.